Director of Research
In the Ley Group, we specialise in developing new synthesis methods and applying them to the construction of biologically important molecules. Over the last 10 years we have completed the total synthesis of 28 natural products including spongistatin 1 (anti-mitotic agent), rapamycin (immunosuppressant), thapsigargin (SERCA pumps inhibitor), azadirachtin (insect antifeedant) and bengazole A (fungicide), taking our group total to 150 completed total syntheses. In addition to our research on natural product synthesis, we also have a new state-of-the-art flow chemistry facility.
For more detailed research information, group members and our publication list please see the group website.
Publications
Diastereoselective aldol reactions with butane-2,3-diacetal protected glyceraldehyde derivatives (vol 4, pg 1471, 2006)
– ORGANIC & BIOMOLECULAR CHEMISTRY
(2006)
4,
1612
Natural Products as an Inspiration for the Discovery of New High‐Throughput Chemical Synthesis Tools
(2006)
2,
51
(doi: 10.1002/9780470085226.ch18)
Asymmetric organocatalytic conjugate addition of malonates to enones using a proline tetrazole catalyst.
– Chem. Commun.
(2005)
66
(doi: 10.1039/b514636d)
Michael, Michael-aldol and Michael-Michael reactions of enolate equivalents of butane-2,3-diacetal protected glycolic acid derivatives
– Organic & Biomolecular Chemistry
(2005)
3,
4095
(doi: 10.1039/b512410g)
Evolution or Revolution: The Challenge to the Modern Medicinal Chemist
(2005)
1
Total Synthesis of Two Novel Subpicomolar Sarco/Endoplasmatic Reticulum Ca2+-ATPase Inhibitors Designed by an Analysis of the Binding Site of Thapsigargin
– Journal of Medicinal Chemistry
(2005)
48,
7005
(doi: 10.1021/jm058036v)
A versatile organocatalyst for the asymmetric conjugate addition of nitroalkanes to enones.
– Chemical communications (Cambridge, England)
(2005)
5346
(doi: 10.1039/b511441a)
A highly selective, organocatalytic route to chiral dihydro-1,2-oxazines.
– Organic Letters
(2005)
7,
4189
(doi: 10.1021/ol051577u)
Total synthesis of Spongistatin 1: A synthetic strategy exploiting its latent pseudo-symmetry
– Angewandte Chemie (International ed. in English)
(2005)
44,
5433
(doi: 10.1002/anie.200502008)
- <
- 46 of 105